Heart failure oral therapies at discharge are associated with better outcome in acute heart failure: a propensity-score matched study

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F18%3A00068517" target="_blank" >RIV/65269705:_____/18:00068517 - isvavai.cz</a>

Alternative codes found

RIV/00216224:14110/18:00102127

Result on the web

<a href="https://onlinelibrary.wiley.com/doi/epdf/10.1002/ejhf.932" target="_blank" >https://onlinelibrary.wiley.com/doi/epdf/10.1002/ejhf.932</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1002/ejhf.932" target="_blank" >10.1002/ejhf.932</a>

Result language

angličtina

Original language name

Heart failure oral therapies at discharge are associated with better outcome in acute heart failure: a propensity-score matched study

Original language description

Aims Heart failure oral therapies (HFOTs), including beta-blockers (BB), renin-angiotensin system inhibitors (RASi) and mineralocorticoid receptor antagonists, administered before hospital discharge after acute heart failure (AHF) might improve outcome. However, concerns have been raised because early administration of HFOTs may worsen patient&apos;s condition. We hypothesized that HFOTs at hospital discharge might be associated with better post-discharge survival.&amp; para;&amp; para;Methods and results The study population was composed of 19 980 AHF patients from the GREAT registry. The primary and secondary and results outcomes were 90-day and 1-year all-cause mortality, respectively. Survival was estimated with univariate and covariate-adjusted Cox proportional hazards regression models for the whole population and after propensity-score matching. HFOTs at discharge were consistently associated with no excess mortality in the unadjusted and adjusted analyses of the whole and matched cohorts. In the matched cohort, BB and RASi at discharge were associated with lower 90-day mortality risks compared to the respective untreated groups [hazard ratio (HR) 0.56, 95% confidence interval (CI) 0.46-0.69; and HR 0.53, 95% CI 0.42-0.66, respectively]. The favourable associations of BB and RASi at discharge with 90-day mortality were present in many subgroups including patients with reduced or preserved left ventricular ejection fraction and persisted up to 1 year after discharge. The combination of RASi and BB was associated with an even lower risk of death than RASi or BB alone.&amp; para;&amp; para;Conclusions Administration of HFOTs at hospital discharge is associated with better survival of AHF patients.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30201 - Cardiac and Cardiovascular systems

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2018

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

European Journal of Heart Failure

ISSN

1388-9842

e-ISSN

—

Volume of the periodical

20

Issue of the periodical within the volume

2

Country of publishing house

US - UNITED STATES

Number of pages

10

Pages from-to

345-354

UT code for WoS article

000429044500022

EID of the result in the Scopus database

2-s2.0-85028469590